Immatics

#药闻简讯# IMA203是由德国$Immatics(IMTX)$ 公司研发的靶向PRAME抗原的自体TCR-T细胞疗法，其I期临床试验（NCT03686124）证实：
✅ 在PRAME阳性晚期实体瘤（尤其黑色素瘤、卵巢癌）中实现高客观缓解率（ORR 54%-60%）和持久临床获益（中位DOR 12.1个月）；
:white_check_...

$Immatics(IMTX)$ S-8 Securities to be offered to employees in employee benefit plans Accession Number: 0000950103-25-008301  Act: 33  Size: 129 KB 网页链接

$Immatics(IMTX)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0000950103-25-006761  Act: 34  Size: 37 MB 网页链接

$Immatics(IMTX)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0000950103-25-006815  Act: 34  Size: 1 MB 网页链接

$Immatics(IMTX)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0000950103-25-007579  Act: 34  Size: 21 KB 网页链接

$Immatics(IMTX)$ SCHEDULE 13G/A [Amend] Statement of Beneficial Ownership by Certain Investors Accession Number: 0000902219-25-000277  Act: 34  Size: 15 KB 网页链接

$Immatics(IMTX)$ 25-NSE Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities Accession Number: 0001354457-25-000599  Act: 34  Size: 3 KB 网页链接

$Immatics(IMTX)$ SCHEDULE 13G/A [Amend] Statement of Beneficial Ownership by Certain Investors Accession Number: 0001104659-25-078657  Act: 34  Size: 13 KB 网页链接

$Immatics(IMTX)$ SCHEDULE 13G/A [Amend] Statement of Beneficial Ownership by Certain Investors Accession Number: 0001897612-25-000381  Act: 34  Size: 7 KB 网页链接

$Immatics(IMTX)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001193125-25-179419  Act: 34  Size: 37 MB 网页链接

$Immatics(IMTX)$ SCHEDULE 13G/A [Amend] Statement of Beneficial Ownership by Certain Investors Accession Number: 0000919574-25-004731  Act: 34  Size: 17 KB 网页链接